VistaGen Therapeutics Competitors

BioXcel Therapeutics (NASDAQ:BTAI) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.

Insider and Institutional Ownership

48.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 3.1% of VistaGen Therapeutics shares are held by institutional investors. 9.4% of BioXcel Therapeutics shares are held by company insiders. Comparatively, 13.7% of VistaGen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for BioXcel Therapeutics and VistaGen Therapeutics, as provided by MarketBeat.com.

BioXcel Therapeutics currently has a consensus target price of $102.00, indicating a potential upside of 83.09%. VistaGen Therapeutics has a consensus target price of $5.6667, indicating a potential upside of 135.13%. Given VistaGen Therapeutics' higher possible upside, analysts clearly believe VistaGen Therapeutics is more favorable than BioXcel Therapeutics.

Profitability

This table compares BioXcel Therapeutics and VistaGen Therapeutics' net margins, return on equity and return on assets.

Volatility & Risk

BioXcel Therapeutics has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, VistaGen Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.

Valuation and Earnings

This table compares BioXcel Therapeutics and VistaGen Therapeutics' gross revenue, earnings per share (EPS) and valuation.

BioXcel Therapeutics is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

VistaGen Therapeutics beats BioXcel Therapeutics on 6 of the 10 factors compared between the two stocks.

Mersana Therapeutics (NASDAQ:MRSN) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings.

Profitability

This table compares Mersana Therapeutics and VistaGen Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for Mersana Therapeutics and VistaGen Therapeutics, as provided by MarketBeat.com.

Mersana Therapeutics currently has a consensus price target of $27.80, indicating a potential upside of 40.55%. VistaGen Therapeutics has a consensus price target of $5.6667, indicating a potential upside of 135.13%. Given VistaGen Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe VistaGen Therapeutics is more favorable than Mersana Therapeutics.

Earnings & Valuation

This table compares Mersana Therapeutics and VistaGen Therapeutics' gross revenue, earnings per share (EPS) and valuation.

VistaGen Therapeutics has lower revenue, but higher earnings than Mersana Therapeutics. Mersana Therapeutics is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

3.1% of VistaGen Therapeutics shares are held by institutional investors. 5.3% of Mersana Therapeutics shares are held by company insiders. Comparatively, 13.7% of VistaGen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Mersana Therapeutics has a beta of 2.54, indicating that its share price is 154% more volatile than the S&P 500. Comparatively, VistaGen Therapeutics has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.

Summary

VistaGen Therapeutics beats Mersana Therapeutics on 9 of the 13 factors compared between the two stocks.

VistaGen Therapeutics (NASDAQ:VTGN) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Analyst Recommendations

This is a breakdown of current ratings and price targets for VistaGen Therapeutics and Rhythm Pharmaceuticals, as reported by MarketBeat.com.

VistaGen Therapeutics currently has a consensus price target of $5.6667, indicating a potential upside of 135.13%. Rhythm Pharmaceuticals has a consensus price target of $50.00, indicating a potential upside of 86.29%. Given VistaGen Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe VistaGen Therapeutics is more favorable than Rhythm Pharmaceuticals.

Insider & Institutional Ownership

3.1% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 88.4% of Rhythm Pharmaceuticals shares are held by institutional investors. 13.7% of VistaGen Therapeutics shares are held by insiders. Comparatively, 9.5% of Rhythm Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk & Volatility

VistaGen Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500.

Valuation and Earnings

This table compares VistaGen Therapeutics and Rhythm Pharmaceuticals' revenue, earnings per share and valuation.

Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares VistaGen Therapeutics and Rhythm Pharmaceuticals' net margins, return on equity and return on assets.

Summary

VistaGen Therapeutics beats Rhythm Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

Arcturus Therapeutics (NASDAQ:ARCT) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

74.3% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 3.1% of VistaGen Therapeutics shares are owned by institutional investors. 12.6% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 13.7% of VistaGen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Arcturus Therapeutics and VistaGen Therapeutics, as reported by MarketBeat.

Arcturus Therapeutics presently has a consensus target price of $73.0769, indicating a potential upside of 33.74%. VistaGen Therapeutics has a consensus target price of $5.6667, indicating a potential upside of 135.13%. Given VistaGen Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe VistaGen Therapeutics is more favorable than Arcturus Therapeutics.

Earnings and Valuation

This table compares Arcturus Therapeutics and VistaGen Therapeutics' revenue, earnings per share (EPS) and valuation.

VistaGen Therapeutics has lower revenue, but higher earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Arcturus Therapeutics and VistaGen Therapeutics' net margins, return on equity and return on assets.

Volatility & Risk

Arcturus Therapeutics has a beta of 3.01, suggesting that its share price is 201% more volatile than the S&P 500. Comparatively, VistaGen Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.

Summary

VistaGen Therapeutics beats Arcturus Therapeutics on 8 of the 12 factors compared between the two stocks.

VistaGen Therapeutics (NASDAQ:VTGN) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Insider and Institutional Ownership

3.1% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 73.8% of Phathom Pharmaceuticals shares are held by institutional investors. 13.7% of VistaGen Therapeutics shares are held by company insiders. Comparatively, 39.8% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for VistaGen Therapeutics and Phathom Pharmaceuticals, as provided by MarketBeat.

VistaGen Therapeutics currently has a consensus price target of $5.6667, suggesting a potential upside of 135.13%. Phathom Pharmaceuticals has a consensus price target of $53.00, suggesting a potential upside of 14.84%. Given VistaGen Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe VistaGen Therapeutics is more favorable than Phathom Pharmaceuticals.

Earnings and Valuation

This table compares VistaGen Therapeutics and Phathom Pharmaceuticals' top-line revenue, earnings per share and valuation.

VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares VistaGen Therapeutics and Phathom Pharmaceuticals' net margins, return on equity and return on assets.

Volatility & Risk

VistaGen Therapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.

VistaGen Therapeutics (NASDAQ:VTGN) and Constellation Pharmaceuticals (NASDAQ:CNST) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and target prices for VistaGen Therapeutics and Constellation Pharmaceuticals, as provided by MarketBeat.

VistaGen Therapeutics currently has a consensus price target of $5.6667, suggesting a potential upside of 135.13%. Constellation Pharmaceuticals has a consensus price target of $46.00, suggesting a potential upside of 71.64%. Given VistaGen Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe VistaGen Therapeutics is more favorable than Constellation Pharmaceuticals.

Insider and Institutional Ownership

3.1% of VistaGen Therapeutics shares are held by institutional investors. 13.7% of VistaGen Therapeutics shares are held by company insiders. Comparatively, 10.6% of Constellation Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares VistaGen Therapeutics and Constellation Pharmaceuticals' net margins, return on equity and return on assets.

Volatility & Risk

VistaGen Therapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Comparatively, Constellation Pharmaceuticals has a beta of 2.8, meaning that its stock price is 180% more volatile than the S&P 500.

Earnings and Valuation

This table compares VistaGen Therapeutics and Constellation Pharmaceuticals' top-line revenue, earnings per share and valuation.

Constellation Pharmaceuticals is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

VistaGen Therapeutics beats Constellation Pharmaceuticals on 8 of the 11 factors compared between the two stocks.